Methotrexate (MTX) is a frequently used chemotherapeutic agent in the treatment of childhood acute lymphoblastic leukaemia (ALL) and lymphoma. Besides oral and intravenous MTX, intrathecal MTX is an essential component of chemotherapy for ALL and is effective in preventing recurrences of central nervous system (CNS) leukaemia. Acute, subacute and chronic neurotoxicity have been observed after the administration of high-dose intravenous and/or intrathecal MTX.1 The incidence varies with the route of administration, with less than 10% of those treated intravenously developing some neurotoxicity compared with up to 40% of patients treated intrathecally in combination with intravenous therapy.2
This article is available only as a PDF. Please click on “Download PDF” to view the full article.
